List view / Grid view
3 February 2015 | By Coulter Partners
Coulter Partners, the Global Life Sciences search specialist, is pleased to announce the appointment of Eskil Westh as Executive Vice President...
3 February 2015 | By Roche
Roche today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. at a price of $50.00 per share...
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
2 February 2015 | By CPhI Worldwide
Experts from CPhI Worldwide have shared their pharma predictions for 2015, suggesting that Continuous Manufacturing and QbD will expand, with FDA becoming ‘industry tutor’. However, pharma concerns about supply chain persist...
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
2 February 2015 | By Abbott
The US FDA has approved two new TECNIS® multifocal intraocular lenses, allowing people with cataracts to choose the best option for their lifestyle...
30 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults...
Warwick Smith, Director General of the BGMA, has welcomed the DofH's decision not to introduce an additional price cut for branded generic medicines...
30 January 2015 | By AstraZeneca and The University of Texas MD Anderson Cancer Center
AstraZeneca and The University of Texas MD Anderson Cancer Center announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes...
30 January 2015 | By GBI Research
The Asia-Pacific therapeutics market for Ovarian Cancer will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, at a Compound Annual Growth Rate of 5.1%, says business intelligence provider GBI Research...
30 January 2015 | By Nabriva Therapeutics AG
Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board...
30 January 2015 | By Virgo Health
European ADPKD Forum report expands current ADPKD evidence base...
30 January 2015 | By electroCore
Non-invasive vagus nerve stimulation (nVNS) ‘improves the safety and tolerability of VNS making it more accessible and facilitating further investigations across a wide range of uses when compared with surgically implanted VNS’ according to a review in the European Journal of Neurology...
29 January 2015 | By The Astellas Innovation Debate
Two thirds (66%) of the population would want to know whether they had a risk of developing a serious illness, such as cancer, if genetic testing were available for free on the NHS...
